• Valérian Rivet, Vincent Sibaud, Jérémie Dion, Salomé Duteurtre, Mélanie Biteau, Cécile Pages, Andréa Pastissier, Karen Delavigne, Pierre Cougoul, Odile Rauzy, and Thibault Comont.
• Service de médecine interne et immuno-pathologie, IUCT - Oncopôle, CHU de Toulouse, 1, avenue Joliot-Curie, 31100 Toulouse, France. Electronic address: Valerian.rivet@gmail.com.
• Rev Med Interne. 2024 Nov 22.

AbstractImmunological checkpoint inhibitors are now part of the oncological therapeutic arsenal in many solid cancers and malignant blood diseases, at the cost of immuno-mediated toxicities, of which dermatological disorders are among the most frequent. The most common, following treatment with anti-PD1 or anti-CTLA4, are maculopapular erythema, pruritus, vitiligo, or lichenoid lesions, but other more atypical conditions may lead to the internist being called upon. Here, we present a case series of these less common dermatological manifestations including fasciitis, dermatomyositis, scleroderma, granulomatosis and immune-induced vasculitis. Some manifestations appear similar to the primary forms or seem to correspond to paraneoplastic syndromes, but some diagnostic and therapeutic particularities are specific to ICI toxicity that the internist must be aware of.Copyright © 2024 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

17 keywords...

hide…